S&P 500 7,755 +0.02% Nasdaq 26,647 +0.16% Dow Jones 53,444 -0.99% FTSE 100 10,720 -1.31% DAX 26,339 +0.06% Nikkei 225 69,220 +3.36% Hang Seng 25,453 -1.87% WTI Crude 84.14 +1.04% Gold 4,476 +1.52% US 10-Year Treasury Yield 4.72 +0.77% S&P 500 7,755 +0.02% Nasdaq 26,647 +0.16% Dow Jones 53,444 -0.99% FTSE 100 10,720 -1.31% DAX 26,339 +0.06% Nikkei 225 69,220 +3.36% Hang Seng 25,453 -1.87% WTI Crude 84.14 +1.04% Gold 4,476 +1.52% US 10-Year Treasury Yield 4.72 +0.77%

LATEST

‘Buy Now, Pay Later’ Lenders Pitch Loans for Needs Like Electricity and Rent●AMD filing reveals unexpected SpaceX and Nutanix bet●SEC data center ruling is removing a key guardrail from Nvidia's $500B AI financing push●Abuja Flooding: Wike blames scavengers as Master Plan faces review●Billionaire Stanley Druckenmiller bailed on Micron and Intel stocks and piled into Amazon●Buc-ee's opened its first Arkansas location and is pushing into six new states●Chevron Strikes Oil and Gas Offshore Angola in Major Discovery●Stop waiting for a dip — Fundstrat’s Mark Newton on stocks to buy now●‘Buy Now, Pay Later’ Lenders Pitch Loans for Needs Like Electricity and Rent●AMD filing reveals unexpected SpaceX and Nutanix bet●SEC data center ruling is removing a key guardrail from Nvidia's $500B AI financing push●Abuja Flooding: Wike blames scavengers as Master Plan faces review●Billionaire Stanley Druckenmiller bailed on Micron and Intel stocks and piled into Amazon●Buc-ee's opened its first Arkansas location and is pushing into six new states●Chevron Strikes Oil and Gas Offshore Angola in Major Discovery●Stop waiting for a dip — Fundstrat’s Mark Newton on stocks to buy now●

Asia

EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70%

Markets-Economic Times · 2h ago · 🇮🇳 India

EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70%

EyePoint's experimental drug Duravyu failed a late-stage trial for a serious eye disease. The company's shares dropped significantly after the disappointing trial results were announced. This failure impacts EyePoint's goal to compete with Regeneron's successful Eylea treatment. Analysts suggest investors will await further study confirmation for the drug's viability. EyePoint plans a new trial and FDA submission for approval in 2027.

Read the full story at Markets-Economic Times →

More Asia

This small-cap ethanol stock to be in focus on Tuesday after additional supply order from OMCs

mint - markets · 47m ago

Bitcoin ETFs suffer biggest outflows since June as crypto sentiment weakens

mint - markets · 51m ago

Yes Bank eyes dollar bond market after six-year hiatus, arrangers appointed: Why now?

mint - markets · 1h ago

Copper hits over six-month high as LME supply concerns mount

Markets-Economic Times · 1h ago